Scientific article
Open access

Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients

Published inTransfusion, vol. 62, no. 10, p. 1997-2011
Publication date2022-10
First online date2022-08-21

Background: Efficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics.

Study design and methods: In a single-center hypothesis-generating prospective case-control study with 1:2 matched dCCP recipients to controls according to disease severity at day 1, hospitalized adults with COVID-19 pneumonia received 2 × 200 ml pathogen-reduced treated dCCP from 2 different donors. We evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 convalescent plasma donors and recipients using multiple antibody assays including a Coronavirus antigen microarray (COVAM), and binding and neutralizing antibody assays. Outcomes were dCCP characteristics, antibody responses, 28-day mortality, and dCCP -related adverse events in recipients.

Results: Eleven of 13 dCCPs (85%) contained neutralizing antibodies (nAb). PRT did not affect dCCP antibody activity. Fifteen CCP recipients and 30 controls (median age 64 and 65 years, respectively) were enrolled. dCCP recipients received 2 dCCPs from 2 different donors after a median of one hospital day and 11 days after symptom onset. One dCCP recipient (6.7%) and 6 controls (20%) died (p = 0.233). We observed no dCCP-related adverse events. Transfusion of unselected dCCP led to heterogeneous SARS CoV-2 antibody responses. COVAM clustered dCCPs in 4 distinct groups and showed endogenous immune responses to SARS-CoV-2 antigens over 14-21 days post dCCP in all except 4 immunosuppressed recipients.

Discussion: PRT did not impact dCCP anti-virus neutralizing activity. Transfusion of unselected dCCP did not impact survival and had no adverse effects. Variable dCCP antibodies and post-transfusion antibody responses indicate the need for controlled trials using well-characterized dCCP with informative assays.

  • COVID-19
  • COVID-19 convalescent plasma
  • SARS-CoV2
  • Neutralizing antibodies
  • Pathogen-reduction treatment
  • Aged
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 / therapy
  • Case-Control Studies
  • Humans
  • Immunization, Passive
  • Middle Aged
  • SARS-CoV-2
  • COVID-19 Serotherapy
Citation (ISO format)
WEISSER, Maja et al. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. In: Transfusion, 2022, vol. 62, n° 10, p. 1997–2011. doi: 10.1111/trf.17083
Main files (1)
Article (Published version)
Secondary files (4)
ISSN of the journal0041-1132

Technical informations

Creation01/31/2023 11:37:16 AM
First validation07/04/2023 2:18:56 PM
Update time07/04/2023 2:18:56 PM
Status update07/04/2023 2:18:56 PM
Last indexation08/31/2023 11:55:00 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack